Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -8.95% is 85% above its 5-year average of -59.70%, near the high end of its 5-year range (-182.75%–15.40%).
As of the fiscal period ended Tuesday, June 30, 2026. 51.37% above its 12-month average of -18.40%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -8.95%.
RETURN ON EQUITY (ROE)
-8.95%
RETURN ON EQUITY (ROE) AVG TTM
-18.40%
RETURN ON EQUITY (ROE) AVG 3Y
-27.49%
RETURN ON EQUITY (ROE) AVG 5Y
-59.70%
RETURN ON EQUITY (ROE) AVG 10Y
-49.09%
RETURN ON EQUITY (ROE) AVG 15Y
-67.84%
RETURN ON EQUITY (ROE) AVG 20Y
-80.44%
CURRENT VS TTM AVG
+51.37%
CURRENT VS 3Y AVG
+67.45%
CURRENT VS 5Y AVG
+85.01%
CURRENT VS 10Y AVG
+81.77%
CURRENT VS 15Y AVG
+86.81%
CURRENT VS 20Y AVG
+88.87%
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+78.70%
vs the sector median at left
Sarepta Therapeutics, Inc.
Market Cap
$1.82B
Return on Equity (ROE)
-8.95%
TTM Avg
-18.40%
3Y Avg
-27.49%
5Y Avg
-59.70%
Market Cap
$1.81B
Return on Equity (ROE)
N/A
TTM Avg
-157.29%
3Y Avg
-33.70%
5Y Avg
49.06%
Market Cap
$1.82B
Return on Equity (ROE)
15.62%
TTM Avg
13.87%
3Y Avg
11.38%
5Y Avg
11.40%
Market Cap
$1.85B
Return on Equity (ROE)
4.88%
TTM Avg
4.47%
3Y Avg
6.79%
5Y Avg
5.89%
Market Cap
$1.85B
Return on Equity (ROE)
-8.14%
TTM Avg
-6.28%
3Y Avg
-6.47%
5Y Avg
-2.03%
Market Cap
$1.79B
Return on Equity (ROE)
N/A
TTM Avg
36.48%
3Y Avg
36.48%
5Y Avg
36.48%
Market Cap
$1.79B
Return on Equity (ROE)
-32.46%
TTM Avg
-24.39%
3Y Avg
-19.07%
5Y Avg
-12.85%
Market Cap
$1.78B
Return on Equity (ROE)
-49.19%
TTM Avg
-59.18%
3Y Avg
-54.84%
5Y Avg
-44.72%
Market Cap
$1.77B
Return on Equity (ROE)
-43.94%
TTM Avg
-43.41%
3Y Avg
-41.23%
5Y Avg
-29.16%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | $1.82B | -8.95% | -18.40% | -27.49% | -59.70% |
| Novavax, Inc. (NVAX)vs › | $1.81B | N/A | -157.29% | -33.70% | 49.06% |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.82B | 15.62% | 13.87% | 11.38% | 11.40% |
| Astrana Health, Inc. (ASTH)vs › | $1.85B | 4.88% | 4.47% | 6.79% | 5.89% |
| Azenta, Inc. (AZTA)vs › | $1.85B | -8.14% | -6.28% | -6.47% | -2.03% |
| Generate Biomedicines, Inc. (GENB)vs › | $1.79B | N/A | 36.48% | 36.48% | 36.48% |
| Xencor, Inc. (XNCR)vs › | $1.79B | -32.46% | -24.39% | -19.07% | -12.85% |
| Absci Corporation (ABSI)vs › | $1.78B | -49.19% | -59.18% | -54.84% | -44.72% |
| Novocure Ltd (NVCR)vs › | $1.77B | -43.94% | -43.41% | -41.23% | -29.16% |
| Palvella Therapeutics, Inc. (PVLA)vs › | $1.87B | -28.45% | -88.46% | -128.76% | -100.86% |
ROE
-8.9%
ROA
-4.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -8.95% |
| 2026-03-31 | 4.32% |
| 2025-12-31 | -62.55% |
| 2025-09-30 | -20.57% |
| 2025-06-30 | -4.27% |
| 2025-03-31 | -21.74% |
| 2024-12-31 | 15.40% |
| 2024-09-30 | 9.98% |
| 2024-06-30 | 4.39% |
| 2024-03-31 | 1.76% |
| 2023-12-31 | -62.37% |
| 2023-09-30 | -90.39% |
| 2023-06-30 | -122.43% |
| 2023-03-31 | -156.47% |
| 2022-12-31 | -182.75% |
| 2022-09-30 | -166.24% |
| 2022-06-30 | -69.74% |
| 2022-03-31 | -41.61% |
| 2021-12-31 | -45.13% |
| 2021-09-30 | -103.53% |
| 2021-06-30 | -130.79% |
| 2021-03-31 | -131.46% |
| 2020-12-31 | -72.74% |
| 2020-09-30 | -67.32% |
| 2020-06-30 | -50.85% |
| 2020-03-31 | -57.29% |
| 2019-12-31 | -87.40% |
| 2019-09-30 | -62.33% |
| 2019-06-30 | -51.89% |
| 2019-03-31 | -29.90% |
| 2018-12-31 | -35.06% |
| 2018-09-30 | -38.29% |
| 2018-06-30 | -30.95% |
| 2018-03-31 | -21.90% |
| 2017-12-31 | -6.42% |
| 2017-09-30 | -16.52% |
| 2017-06-30 | -32.86% |
| 2017-03-31 | -28.76% |
| 2016-12-31 | -79.38% |
| 2016-09-30 | -59.59% |
| 2016-06-30 | -196.52% |
| 2016-03-31 | -157.05% |
| 2015-12-31 | -115.59% |
| 2015-09-30 | -162.10% |
| 2015-06-30 | -107.06% |
| 2015-03-31 | -84.22% |
| 2014-12-31 | -54.83% |
| 2014-09-30 | -35.01% |
| 2014-06-30 | -37.68% |
| 2014-03-31 | -42.88% |
| 2013-12-31 | -45.30% |
| 2013-09-30 | -66.90% |
| 2013-06-30 | -194.50% |
| 2013-03-31 | -166.89% |
| 2012-12-31 | -98.07% |
| 2012-06-30 | -67.09% |
| 2012-03-31 | -155.86% |
| 2011-12-31 | -7.47% |
| 2011-09-30 | -26.93% |
| 2011-06-30 | -33.64% |
| 2010-09-30 | -504.64% |
| 2010-06-30 | -258.32% |
| 2010-03-31 | -105.73% |
| 2009-12-31 | -106.47% |
| 2009-09-30 | -152.92% |
| 2009-06-30 | -733.44% |
| 2009-03-31 | -43.10% |
| 2008-12-31 | -152.26% |
| 2008-09-30 | -164.88% |
| 2008-06-30 | -131.47% |
| 2008-03-31 | -167.00% |
| 2007-12-31 | -111.52% |
| 2007-09-30 | -220.84% |
| 2007-06-30 | -137.81% |
| 2007-03-31 | -102.50% |
| 2006-12-31 | -82.40% |
| 2006-09-30 | -61.53% |
| 2006-06-30 | -44.31% |
| 2006-03-31 | -36.20% |
| 2005-12-31 | -31.08% |
| 2005-09-30 | -46.26% |
| 2005-06-30 | -53.16% |
| 2005-03-31 | -52.38% |
| 2004-12-31 | -94.32% |
| 2004-09-30 | -73.76% |
| 2004-06-30 | -62.21% |
| 2004-03-31 | -43.51% |
| 2003-12-31 | -33.68% |
| 2003-09-30 | -44.57% |
| 2003-06-30 | -46.86% |
